Elevated homocysteine levels are associated with venous and arterial thromboses and an adverse prognosis. We hypothesized that this may be due to increased thrombogenesis as a result of direct damage to the vascular endothelium. To investigate this hypothesis further venous blood was obtained from 83 patients with essential hypertension (43 male; mean age 54Ϯ15.9) and from 25 healthy controls (13 male; mean age 56Ϯ11.8). Homocysteine (HPLC) and von Willebrand factor (vWf, a marker of endothelial dysfunction) (ELISA) were measured in citrated plasma.
These patients were followed-up for a mean of 44.6 months (range 1-66). 17 subjects (22%) experienced a cardiovascular event (myocardial infarction, stroke or cardiovascular death). These individuals were older (mean age 65.1 vs 51.3 pϭ0.0002) and had had hypertension for longer (15.6 vs 73 months pϭ0.018). They had no significant elevation in homocysteine (13.9 vs 11.4 zmol/L, pϭ0.07) or vWf (124 vs 112 iU/dL, pϭ0.014) levels.
There were no significant correlations between homocysteine or vWf. Conclusion: Essential hypertension is associated with raised plasma homocysteine levels but there did not appear to be a significant relationship to endothelial damage (vWf) or prognosis. Structure and function of blood vessels vary along the vascular tree, and alterations in hypertension are also different. The aim of this study is to determine whether noninvasive measurement of endothelial function in conduit arteries reflects that of subcutaneous resistance arteries measured in vitro. Ten male hypertensive patients (age: 49Ϯ2 years) were studied. Flow-mediated dilation (FMD) during reactive hyperemia (endothelium-dependent) and sublingual nitroglycerin (NTG)-induced dilation (endothelium-independent) were assessed in brachial arteries by ultrasound. Structure and acetylcholine (10 Ϫ9 to 10 Ϫ4 mol/L)-and sodium nitroprusside (SNP; 10 Ϫ8 to 10 Ϫ3 mol/L)-induced vasorelaxation were measured in gluteal subcutaneous resistance arteries in vitro, using a pressurized myograph. Dilatory responses in brachial arteries were compared to those in resistance arteries. Brachial artery FMD and NTG-induced dilation were 8.3Ϯ1.5 and 18.4Ϯ1.2%, respectively. In subcutaneous resistance arteries, the media/lumen ratio was 8.9Ϯ0.5%, and the maximal acetylcholine-and SNP-responses were 75Ϯ4 and 86Ϯ2%, respectively. FMD was strongly correlated with maximal acetylcholine responses (adjusted r 2 ; 0.76, pϽ0.001, statistic power with alphaϭ0.05; Ͼ0.90), and weakly correlated with media/lumen ratio in resistance arteries (adjusted r 2 ; 0.34, pϭ0.058). By multivariate analysis, FMD predicted resistance artery endothelial function independently of age, body mass index, and blood lipid status. In conclusion, endothelial dilatory responses are similar in small and large arteries in hypertensive patients. FMD in the brachial artery is a powerful predictor of endothelial function in human resistance arteries, but not of their structure. It is still uncertain whether improvement of endothelial function by HMG-CoA reductase inhibitors may assist to better blood pressure control in hypertensive patients. This study aimed to examine the effects of coadministration of low dose Aspirin and Simvastatin on blood pressure, on endothelial function, tonus and elasticity of brachial artery in non-hyperlipidemic, treated hypertensive subjects. 23 non-hyperlipidemic (LDL ϭ 106,4Ϯ16,3mg/dl) subjects (M:14, F:9) with treated arterial hypertension, (BP syst 148.4Ϯ9.05mm/Hg, BP diast 82.4Ϯ4.7mm/Hg) 21 to 70 years of age (mean 54Ϯ12) were randomized in two groups to receive in addition to their antihypertensive medications: Group A: Aspirin 75mg per day for 8 weeks, Group B: The sameϩ Simvastatin 10mg/day for the first 4 weeks. Using high resolution ultrasound, brachial artery diameter was measured at rest and during reactive hyperemia (RH) after 4.5min. of pressure 250mm/Hg on forearm, (with flow increase causing endothelial-dependent dilation,) Flow mediated dilation (FMD) was calculated. Brachial artery tonus and elasticity were measured by analyzing pulsatile variations and brachial artery pulse contour, using pulse echo ultrasound (Device the Ultrasound brain Vessel Scanner. Inta Medics Ltd. Israel). In the group B we observed a significant reduction of both systolic (17,8Ϯ4,7mm/Hg, pϽ 0.001) and diastolic (6,01Ϯ2,08mm/Hg, pϽ0.05) blood pressure, improvement of FMD (‚FMD 2-1 17,2 Ϯ 6,3 %, p Ͻ 0.001) and tonus (T 1 /T 2 147,3Ϯ14,8%, p Ͻ 0.001) of brachial artery after one month, while discontinuation of simvastatin there was elevation of systolic (‚SBP 3-2 8,99Ϯ3,61 mm/Hg, pϽ 0.05) and diastolic (‚DBP 3-2 4,13 Ϯ2,96mm/Hg, p Ͻ 0.05) blood pressure and deterioration of FMD (‚FMD 3-2 13.3Ϯ5,9%, pϽ0.001).
In the group A no significant changes in any parameter was seen along the two months. Brachial artery elasticity was not changed in both groups. Simvastatin 10mg/d improves (while aspirin 75 mg/d does not) endothelial dysfunction in non-hyperlipidemic hypertensive subjects and may assist to better blood pressure control.
